Skip to main content

Table 1 Basic characteristics of the included studies

From: Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis

Study

Year

Cancer type

Country

Study type

Study period

No. of cases

Male patients, n (%)

Age, years

Survival type

Treatment

Stage

ALI cutoff value

Cutoff selection method

Jafri et al. [25]

2013

NSCLC

USA

R

2000–2011

173

116 (67%)

57 (34–88)

OS, PFS

No surgery

Metastatic

18.4

ROC curve analysis

He et al. [29]

2015

SCLC

China

R

2006–2011

365

310 (84.9%)

59 (22–82)

OS

No surgery

Mixed

19.50

Cutoff Finder

Kim et al. [30]

2016

SCLC

Korea

R

2010–2015

186

156(83.9%)

68.9 ± 9.4

OS

No surgery

Mixed

31.1

Cutoff value

Park et al. [31]

2017

Diffuse large B cell lymphoma

Korea

R

2006–2014

212

142 (67%)

59 (26–76)

OS, PFS

No surgery

Mixed

15.5

ROC curve analysis

Bacha et al. [32]

2017

NSCLC

France

R

2010–2012

41

41 (100%)

55 (41–76)

OS

No surgery

Metastatic

23.2

ROC curve analysis

Kobayashi et al. [33]

2018

NSCLC

Japan

R

2009–2014

166

74 (44.6%)

–

OS

Surgery

Non-metastatic

22.2

ROC curve analysis

Tomita et al. [34]

2018

NSCLC

Japan

R

2008–2012

341

173 (50.7%)

69 (median)

OS

Surgery

Non-metastatic

37.66

Cutoff Finder

Shibutani et al. [35]

2019

Colorectal cancer

Japan

R

2008–2016

159

87 (54.7%)

65 (18–89)

OS

No surgery

Metastatic

28.9

ROC curve analysis

Jank et al. [36]

2019

Head and neck squamous cell carcinoma

Austria

R

2002–2012

93

72 (77.4%)

58 (27–72)

OS, DFS

Surgery

Mixed

37.6

Cutoff value

  1. Abbreviations: NSCLC non-small cell lung cancer, SCLC small cell lung cancer, R retrospective, OS overall survival, PFS progression-free survival, DFS disease-free survival, Mixed included patients with metastatic and non-metastatic disease, ALI advanced lung cancer inflammation index, ROC receiver operating characteristic curve